Gabriele Ricci Sells 25,088 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Gabriele Ricci sold 25,088 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $429,004.80. Following the sale, the insider directly owned 171,654 shares in the company, valued at $2,935,283.40. This trade represents a 12.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK traded down $0.06 during midday trading on Wednesday, hitting $17.42. The company’s stock had a trading volume of 2,004,364 shares, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90. The firm’s fifty day moving average price is $16.49 and its 200-day moving average price is $17.13. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The firm has a market cap of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The firm had revenue of $6.90 billion for the quarter. On average, sell-side analysts forecast that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.

Institutional Trading of Takeda Pharmaceutical

Institutional investors have recently made changes to their positions in the stock. Capital Research Global Investors boosted its holdings in shares of Takeda Pharmaceutical by 0.6% in the fourth quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after acquiring an additional 82,643 shares in the last quarter. UBS Group AG raised its holdings in Takeda Pharmaceutical by 46.4% during the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after purchasing an additional 1,869,323 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its position in Takeda Pharmaceutical by 100.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock worth $88,596,000 after purchasing an additional 2,854,069 shares during the period. Goldman Sachs Group Inc. boosted its stake in Takeda Pharmaceutical by 15.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after purchasing an additional 692,404 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Takeda Pharmaceutical by 14.2% during the 1st quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after purchasing an additional 370,800 shares during the period. 9.17% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TAK has been the topic of a number of research reports. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.